Back to Search
Start Over
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials
- Publication Year :
- 2017
-
Abstract
- Different treatment strategy based on tumor etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-positive HCC patients may be the best strategy for improvement the outcome of these patients
- Subjects :
- Oncology
Sorafenib
medicine.medical_specialty
medicine.disease_cause
Hepatology
Gastroenterology
HCV Positive
hepatocellular carcinoma, outcome, sorafenib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Regorafenib
Internal medicine
medicine
Carcinoma
Hepatitis B virus
Phenylurea Compounds
business.industry
Hepatitis C
medicine.disease
digestive system diseases
chemistry
030220 oncology & carcinogenesis
Hepatocellular carcinoma
030211 gastroenterology & hepatology
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....ea1318f340760af0dd64e971e2fceb63